View Older Stories View More Recent Stories

Nov 16, 2020 08:30AM Urban League, CSL Behring Partner to Address Community Needs including Public Health, Workforce Diversity, Leadership Development
Nov 10, 2020 08:10AM CSL Behring To Present New Real-World Data on Outcomes Following Acute Coronary Syndrome at the American Heart Association (AHA) Virtual Scientific Sessions 2020
Nov 5, 2020 08:10AM CSL Behring Publishes Design for First-Ever Outcomes Study of ApoA-I to Reduce Risk of Cardiovascular Events in Heart Attack Patients
Nov 2, 2020 08:00AM Orphan Drug Designation Granted for CSL Behring's Investigational Plasma-Derived Hemopexin Therapy for Sickle Cell Disease
Sep 28, 2020 08:10AM U.S. Food and Drug Administration Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) for Prevention of Hereditary Angioedema (HAE) Attacks in Pediatric Patients
Jul 9, 2020 08:33AM CSL Behring Announces Professor Heimburger Awards in Advance of ISTH 2020 Virtual Congress
Jul 6, 2020 08:33AM In Fight Against COVID-19, CSL Behring Begins Trial to Evaluate Monoclonal Antibody (CSL312) for Respiratory Distress
Jul 3, 2020 02:30AM IDELVION® Becomes First and Only Factor IX Therapy with 21-Day Prophylactic Dosing
Jun 24, 2020 06:28PM CSL Behring Agrees to Acquire Novel Late-Stage Gene Therapy Candidate for Hemophilia B Patients from uniQure
Jun 12, 2020 08:20AM CSL Behring to Attend and Sponsor World Federation of Hemophilia First Ever Virtual Summit
Jun 8, 2020 04:00PM CSL Behring to Acquire Biotech Company Vitaeris
Jun 8, 2020 02:00AM CSL Behring Presents Results for Garadacimab as Preventive Treatment in Hereditary Angioedema
Jun 2, 2020 10:00AM CSL Behring and Seattle Children's Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases
Apr 21, 2020 08:00AM CSL Behring Announces Results from Three Analyses of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) in Primary Immunodeficiency (PI)
Feb 13, 2020 09:00AM University City Science Center partnership with CSL Behring accelerates the search for new biotherapies at the University of Pittsburgh and the University of Delaware
Feb 11, 2020 05:10PM PRIVIGEN® (Immune Globulin Intravenous (Human), 10% Liquid) Granted Orphan-Drug Designation for the Investigational Treatment of Systemic Sclerosis (SSc)
Jan 21, 2020 11:21AM Forbes Magazine Ranks CSL Behring Among Best Employers for Diversity
Jan 9, 2020 12:35PM Global Biotech Leader CSL to Present at 38th Annual J.P. Morgan Healthcare Conference
Dec 9, 2019 08:19AM HIZENTRA® (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Oct 24, 2019 09:20AM Harvard Business Review Names CSL's Paul Perreault Among Best Performing CEOs in the World
Jul 1, 2019 06:15PM CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019
Jun 20, 2019 07:00AM CSL Behring to showcase clinical advances and insights in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with Hizentra ® [human normal immunoglobulin, 20%, subcutaneous], at the 2019 Periph
May 16, 2019 03:15AM Top Coagulation Researchers Awarded Grants to Support Advancements in the Care of Patients with Bleeding Disorders
Apr 25, 2019 08:37AM CSL Behring Delivers on its Continued Commitment to Alpha 1 Patients with FDA Approval of Convenient Single-Vial Dosing for ZEMAIRA® [Alpha1-Proteinase Inhibitor (Human)]
Mar 26, 2019 12:21PM Japan's Ministry of Health, Labour and Welfare Approves CSL Behring Immunoglobulins to Treat Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Feb 4, 2019 09:33AM CSL Behring Extends Support of World Federation of Hemophilia Programs
Jan 16, 2019 09:50AM CSL Named One of the Best Employers in the US for Diversity
Jan 7, 2019 08:30AM Global Biotech Leader CSL to Present at J.P. Morgan Healthcare Conference on Wednesday, January 9
Dec 6, 2018 09:10AM CSL CEO Paul Perreault Earns 2018 Most Admired CEOs Recognition from the Philadelphia Business Journal
Sep 18, 2018 09:45AM CSL Named One of the Top Companies in the World for Diversity and Inclusion
Sep 12, 2018 08:00AM The Arizona Bioscience Company of the Year is on a Mission to Cure the Uncurable
Aug 23, 2018 09:00AM IDELVION® 3500 IU Vials Now Available to Provide Convenience to Patients
Jul 20, 2018 09:00AM CSL Behring Hosts Symposium on Managing CIDP with Immunoglobulin, Supports 14 Scientific Posters and Two Oral Presentations at the 2018 Peripheral Nerve Society Annual Meeting
Jun 22, 2018 06:00AM /C O R R E C T I O N -- CSL Behring/
Jun 22, 2018 06:00AM A New Generation Of Coagulation Specialists Is Advancing Research With Support From CSL Behring Global Grant
May 31, 2018 09:00AM IDELVION® Newly Approved 3500 IU Vial to Provide Convenience to Patients Using Larger Volumes
May 14, 2018 03:00PM Hemophilia Association Of New Jersey Recognizes CSL CEO Paul Perreault As "Humanitarian Man Of The Year"
Apr 26, 2018 09:00AM Patient Advocacy Groups Focus On Key Issues Affecting Patients
Apr 20, 2018 08:30AM CSL Behring, Leader in Rare Diseases, Showcases Innovations in Neuromuscular Medicine (NMM) at the 2018 American Academy of Neurology Annual Meeting
Apr 12, 2018 10:15AM Life-Saving Medicines Donated For Patients In The Developing World
Mar 23, 2018 09:55AM CSL Behring Announces First Patient Enrollment in Phase 3 Clinical Trial of CSL112 to Assess Reduction of Early Recurrent Cardiovascular Events in Heart Attack Survivors
Mar 20, 2018 09:00AM Forbes Magazine Names CSL Limited Among Top 50 Employers in the World
Mar 16, 2018 08:00AM FDA Approves Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Mar 15, 2018 09:00AM CSL Behring Receives Patient Impact Award For Subcutaneous Prophylactic Treatment To Prevent Hereditary Angioedema Attacks
Mar 13, 2018 12:19PM CSL CEO Paul Perreault Calls on Industry to Improve Patients' Access to Medicines
Dec 4, 2017 04:25PM CSL Behring Advances to Phase 3 Cardiovascular Outcomes Trial for CSL112, its Novel Apolipoprotein A-I (Human) Infusion Therapy
Nov 9, 2017 08:00AM Lancet Neurology Publishes Results from CSL Behring Phase III Study of Hizentra® (Immune Globulin Subcutaneous [Human] 20% liquid) as Maintenance Therapy in Patients with Chronic Inflammatory Demyeli
Oct 29, 2017 02:30PM Data on the Preventive Effects of HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) in Subjects with Very Frequent HAE Attacks Presented by CSL Behring at the 2017 ACAAI Annual Scientific Meetin
Oct 24, 2017 08:00AM New Data for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) to be presented at the 2017 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
Oct 12, 2017 09:00AM CSL Behring Trains Employees to Save Lives in Their Communities and Workplace with CPR; AHA Encourages Other Businesses to Do the Same
View More Recent Stories View Older Stories